Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong domestic demand, and said the U.S. freezing aid for some drug ...
Cipla share price will remain in focus after the United States Food and Drug Administration (USFDA) has classified the ...
17don MSN
Results: Pharmaceutical major Cipla on Tuesday reported a 49 per cent year-on-year (YoY) increase in its consolidated net profit for the December quarter (Q3 FY25) at Rs 1,574.6 crore, from Rs 1,068.5 ...
During the year, the Company issued and allotted 2,16,469 equity shares of Rs. 2/- each to its employees under the Employee Stock Option Scheme 2013-A and the Cipla Employee StockAppreciation ...
Cipla's stock settled 2.2% higher at ₹1,427 on Tuesday on the National Stock Exchange. The company expects to launch its breast cancer drug Abraxane, which was originally slated for a rollout in ...
The USFDA has conducted routine cGMP inspection at the facility in the period between November 7 through November 13, 2024.
Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.
Mumbai: Cipla has announced that the Company will invest approx. ZAR 900 million in equity share capital of Cipla Medpro ...
Mumbai: Cipla has announced that the United States Food and Drug Administration (USFDA) has classified the inspection at the Company’s manufacturing facility in Virgonagar, Bengaluru, India ...
Samvardhana Motherson, Garden Reach Shipbuilders, NLC India and Central Bank of India are also among the stocks to watch in ...
CMSA, is a wholly owned subsidiary of Cipla, and is the holding company for the group operations in South Africa. The group is involved in the manufacturing, marketing, and supply of pharmaceutical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback